Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,107 public trials 2,039 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

Investigation of Tipifarnib in Treatment of Subjects With Peripheral T-Cell Lymphoma (PTCL) That Have Not Responded to Standard Therapy

NCT02464228

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Stanford University Medical Center Palo Alto, California, United States
  • Yale University, Yale Cancer Center New Haven, Connecticut, United States
  • H. Lee Moffitt Cancer Center & Research Institute, Inc. Tampa, Florida, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View all 13 locations
View Trial Details
Completed

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma

NCT01796171

Conditions
Follicular Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • University Of Arkansas For Medical Sciences Little Rock, Arkansas, United States
  • Pacific Shores Medical Group Long Beach, California, United States
  • University of California, San Francisco (UCSF) San Francisco, California, United States
  • Boca Raton Regional Hospital Boca Raton, Florida, United States
View all 96 locations
View Trial Details
Completed

Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients

NCT03610724

Conditions
Burkitt Lymphoma, DNA Virus Infections, Epstein-Barr Virus Infections, +17 more
Locations
  • Childrens Hospital Los Angeles Los Angeles, California, United States
  • UCSF Medical Center San Francisco, California, United States
  • Johns Hopkins Oncology Center ORA Baltimore, Maryland, United States
  • Dana Farber Cancer Institute Dept.of DFCI Boston, Massachusetts, United States
View all 26 locations
View Trial Details
Completed

Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

NCT03194867

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • University of Colorado-Site Number:8400001 Denver, Colorado, United States
  • University of Kansas Medical Center-Site Number:8400003 Kansas City, Kansas, United States
  • Memorial Sloan-Kettering Cancer Center-Site Number:8400002 New York, United States
  • Fox Chase Cancer Center-Site Number:8400004 Philadelphia, Pennsylvania, United States
View all 30 locations
View Trial Details

Related conditions